Treatment Clinical Trials for Melanoma

Clinical trials are research studies that involve people. The clinical trials on this list are for melanoma treatment. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 251-264 of 264
< Previous 1 ... 9 10 11

  • CBL0137 in Treating Patients with Advanced Extremity Melanoma or Sarcoma

    This phase I trial studies best dose and side effects of CBL0137 in treating patients with extremity melanoma or sarcoma that has spread to other places in the body. Drugs, such as CBL0137, may work by binding to tumor cell deoxyribonucleic acid (DNA) to stop the cell from growing further.
    Location: Roswell Park Cancer Institute, Buffalo, New York

  • Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients with Uveal Melanoma

    This phase II trial studies how well stereotactic body radiation therapy and aflibercept work in treating patients with uveal melanoma. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Aflibercept may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving stereotactic body radiation therapy followed by aflibercept may work better in treating patients with uveal melanoma.
    Location: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

  • Stereotactic Body Radiation Therapy with Ipilimumab and Nivolumab in Treating Patients with Metastatic Melanoma

    This phase II trial studies how well stereotactic body radiation therapy works when given together with ipilimumab and nivolumab in treating patients with melanoma that has spread to other parts in the body. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Monoclonal antibodies, such as ipilimumab and nivolumab, may interfere with the ability of tumor cells to grow and spread. Giving stereotactic body radiation therapy with ipilimumab and nivolumab may work better in treating patients with melanoma.
    Location: UT Southwestern / Simmons Cancer Center-Dallas, Dallas, Texas

  • Nivolumab and Ipilimumab with or without Sargramostim in Treating Patients with Stage III-IV Melanoma That Cannot Be Removed by Surgery

    This randomized phase II / III trial studies the side effects and best dose of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery. Monoclonal antibodies, such as ipilimumab and nivolumab, may kill tumor cells by blocking blood flow to the tumor, by stimulating white blood cells to kill the tumor cells, or by attacking specific tumor cells and stop them from growing or kill them. Colony-stimulating factors, such as sargramostim, may increase the production of white blood cells. It is not yet known whether nivolumab and ipilimumab are more effective with or without sargramostim in treating patients with melanoma.
    Location: 399 locations

  • Aldesleukin and Pembrolizumab in Treating Participants with Stage III and IV Melanoma and Renal Cell Cancer

    This phase I / II trial studies the side effects and how well pembrolizumab and aldesleukin work in treating participants with stage III and IV melanoma or renal cell cancer. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Interleukins, such as aldesleukin, are proteins made by white blood cells and other cells in the body and may help regulate immune response. Giving pembrolizumab and aldesleukin may work better in treating melanoma and renal cell cancer.
    Location: University of Virginia Cancer Center, Charlottesville, Virginia

  • Pembrolizumab and Stereotactic Body Radiation Therapy in Treating Patients with Metastatic Melanoma or Non-small Cell Lung Cancer

    This phase Ib / IIa trial studies the side effects and best dose of stereotactic body radiation therapy when given together with pembrolizumab in treating patients with melanoma or non-small cell lung cancer that has spread to other places in the body. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Monoclonal antibodies, such as pembrolizumab, may block specific proteins which may strengthen the immune system and control tumor growth. Giving stereotactic body radiation therapy may prolong the response to pembrolizumab in patients with melanoma or non-small cell lung cancer.
    Location: Yale University, New Haven, Connecticut

  • Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum

    Background: During recent years, cancer-testis (CT) antigens (CTA), particularly those encoded by genes on the X chromosome (CT-X genes), have emerged as attractive targets for cancer immunotherapy. Whereas malignancies of diverse histologies express a variety of CTAs, immune responses to these proteins appear uncommon in cancer patients, possibly due to low-level, heterogeneous antigen expression, as well as immunosuppressive regulatory T cells present within tumor sites and systemic circulation of these individuals. Conceivably, vaccination of cancer patients with tumor cells expressing high levels of CTAs in combination with regimens that deplete or inhibit T regulatory cells will induce broad immunity to these antigens. In order to examine this issue, patients with primary lung and esophageal cancers, pleural mesotheliomas, thoracic sarcomas, thymic neoplasms and mediastinal germ cell tumors, as well as sarcomas, melanomas, germ cell tumors, or epithelial malignancies metastatic to lungs, pleura or mediastinum with no evidence of disease (NED) or minimal residual disease (MRD) following standard multidisciplinary therapy will be vaccinated with H1299 tumor cell lysates with Iscomatrix adjuvant. Vaccines will be administered with or without metronomic oral cyclophosphamide (50 mg PO BID x 7d q 14d), and celecoxib (400 mg PO BID). Serologic responses to a variety of recombinant CTAs as well as immunologic responses to autologous tumor or epigenetically modified autologous EBVtransformed lymphocytes will be assessed before and after a six month vaccination period. Primary Objectives: 1. To assess the frequency of immunologic responses to CTAs in patients with thoracic malignancies following vaccinations with H1299 cell lysate / Iscomatrix(TM) vaccines alone in comparison to patients with thoracic malignancies following vaccinations with H1299 cell lysate / Iscomatrix vaccines in combination with metronomic cyclophosphamide and celecoxib. Secondary Objectives: 1. To examine if oral metronomic cyclophosphamide and celecoxib therapy diminishes the number and percentage of T regulatory cells and diminishes activity of these cells in patients with thoracic malignancies are at risk of recurrence. 2. To examine if H1299 cell lysate / Iscomatrix(TM) vaccination enhances immunologic response to autologous tumor or epigenetically modified autologous EBV-transformed lymphocytes (B cells). Eligibility: - Patients with histologically or cytologically proven small cell or non-small cell lung cancer (SCLC;NSCLC), esophageal cancer (EsC), malignant pleural mesothelioma (MPM) , thymic or mediastinal germ cell tumors, thoracic sarcomas, or melanomas, sarcomas, or epithelial malignancies metastatic to lungs, pleura or mediastinum who have no clinical evidence of active disease (NED), or minimal residual disease (MRD) not readily accessible by non-invasive biopsy or resection / radiation following standard therapy completed within the past 26 weeks. - Patients must be 18 years or older with an ECOG performance status of 0 2. - Patients must have adequate bone marrow, kidney, liver, lung and cardiac function. - Patients may not be on systemic immunosuppressive medications at time vaccinations commence. Design: - Following recovery from surgery, chemotherapy, or chemo / XRT, patients with NED or MRD will be vaccinated via IM injection with H1299 cell lysates and Iscomatrix(TM) adjuvant monthly for 6 months. - Vaccines will be administered with or without with metronomic oral cyclophosphamide and celecoxib. - Systemic toxicities and immunologic response to therapy will be recorded. Pre and post vaccination serologic and cell mediated responses to a standard panel of CT antigens as well as autologous tumor cells (if available) and EBV-transformed lymphocytes will be assessed before and after vaccination. - Numbers / percentages and function of T regulatory cells in peripheral blood will be assessed before, during, and after vaccinations. - Patients will be followed in the clinic with routine staging scans until disease recurrence. - The trial will randomize 28 evaluable patients per arm to either receive vaccine alone or vaccine plus chemotherapy in order to have 80% power to determine if the frequency of immune responses on the combination arm exceeds that of the vaccine alone arm, if the expected frequencies of immune responses on the two arms were 20% and 50%, using a one-sided 0.10 alpha level Fisher s exact
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • Nab-Paclitaxel and Bevacizumab in Treating Patients with Unresectable Stage IV Melanoma or Gynecological Cancers

    This phase I trial studies the side effects and best dose of nab-paclitaxel and bevacizumab in treating patients with stage IV melanoma that cannot be removed by surgery or with cancer of the cervix, endometrium, ovary, fallopian tube or peritoneal cavity. Drugs used in chemotherapy, such as nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as bevacizumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving nab-paclitaxel and bevacizumab may kill more tumor cells than nab-paclitaxel alone.
    Location: Mayo Clinic, Rochester, Minnesota

  • Vaccine Therapy in Treating Patients with Stage IIIB-IV Melanoma

    This phase I trial studies the side effects and best dose of vaccine therapy in treating patients with stage IIIB-IV melanoma. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Giving booster vaccinations may make a stronger immune response and prevent or delay the recurrence of cancer.
    Location: 3 locations

  • Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

    The purpose of this study is to determine how safe and how well POL-103A works in preventing the relapse of melanoma after patients who have undergone surgery.
    Location: 2 locations

  • Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients with Advanced Melanoma, Lung, or Kidney Cancer

    This phase II trial studies how well image guided hypofractionated radiation therapy works with nelfinavir mesylate, pembrolizumab, nivolumab, and atezolizumab in treating patients with melanoma, lung cancer, or kidney cancer that has spread. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Nelfinavir mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, nivolumab and atezolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving hypofractionated radiation therapy, nelfinavir mesylate, pembrolizumab, nivolumab and atezolizumab may work better in treating patients with melanoma, lung, or kidney cancer.
    Location: See Clinical Trials.gov

  • CDX-1401 and Poly-ICLC Vaccine Therapy with or without CDX-301 in Treating Patients with Stage IIB-IV Melanoma

    This randomized phase II trial studies how well DEC-205 / NY-ESO-1 fusion protein CDX-1401 (CDX-1401) and neoantigen-based melanoma-poly-ICLC vaccine (poly-ICLC) vaccine therapy work when given with or without recombinant flt3 ligand (CDX-301) in treating patients with stage IIB-IV melanoma. The cancer vaccine CDX-1401 attaches to a protein that is made in tumor cells. The vaccine helps the body recognize the tumor to fight the cancer. The CDX-301 vaccine may help the body make more of the tumor fighting cells, known as dendritic cells. The poly-ICLC vaccine stimulates the immune system and may help these dendritic cells mature so that they can recognize the tumor. It is not yet known whether CDX-1401 and poly-ICLC will work better with or without CDX-301 in treating melanoma.
    Location: 5 locations

  • Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation

    - An Open Label, Multicenter, Phase I Extension Study of an Oral Cdk Inhibitor P1446A-05 Administered with an Oral BRAF Inhibitor Vemurafenib (Zelboraf®) in Patients with Advanced or Inoperable Malignant Melanoma with BRAF Mutation - The primary objective is to determine the safety, maximum tolerated dose (MTD), and dose limiting toxicity (DLT) of the co-administration of P1446A-05 with vemurafenib, in melanoma patients with BRAF mutation
    Location: See Clinical Trials.gov

  • Vaccine Therapy in Treating Patients with Recurrent Stage IIIC-IV Melanoma

    This phase I trial studies the side effects and the best dose of vaccine therapy in treating patients with stage IIIC-IV melanoma that has come back. Vaccines made from a person's tumor cells and proteins may help the body build an effective immune response to kill tumor cells.
    Location: See Clinical Trials.gov


< Previous 1 ... 9 10 11